3 standout digital innovations in pharma this year

IDEA Pharma just released its Digital Innovation Index. Here are the top companies they identified and some of the standout advances the industry made.

By Meagan Parrish • Dec. 1, 2023

Octave Bioscience is navigating the Parkinson’s labyrinth with Michael J. Fox’s help

A grant from the notorious Parkinson’s foundation has sped up Octave’s timeline to further advance biomarker development in the field.

By Kelly Bilodeau • Nov. 29, 2023

Explore the Trendline➔

Cell and gene therapies

How the industry is overcoming hurdles in cell and gene therapy space and pushing for the next generation of treatments.

By PharmaVoice staff

Pharma benefited from basing business overseas. An international tax effort could spur a rethink.

U.S. tax law changes six years ago slashed large pharma companies' rates and saved them billions. Now, a push for an international floor could disrupt their R&D accounting.

By Jonathan Gardner • Nov. 29, 2023

The head of AstraZeneca’s new digital health business on how the pharma is leveraging tech

Cristina Durán, formerly AstraZeneca’s chief digital officer of R&D and now head of digital health company Evinova, believes data will help pharma screen and treat patients earlier in their disease.

By Michael Gibney • Nov. 28, 2023

Biopharma’s top 5 IPOs of 2023 (so far)

Despite one major outlier, 2023’s IPOs haven’t hit the heights of the past three years.

By Alexandra Pecci • Nov. 28, 2023

How EMD Serono plans to hit its lofty goals in R&D

The company’s global heads of oncology R&D reveal how strategic partnerships are key to its launch plans following layoffs in the U.S.

By Alexandra Pecci • Nov. 27, 2023

As alcohol-related deaths climb, new drugs could curb the urge to drink

A drug developed by Kinnov Therapeutics halved alcohol consumption in heavy drinkers in a mid-stage study.

By Kelly Bilodeau • Nov. 27, 2023

The biopharma COO’s playbook

Connie Chang, COO at ONL Therapeutics, describes what it takes to bring a CEO’s vision to life.

By Alexandra Pecci • Nov. 21, 2023

Biohaven wants to muscle in on the Ozempic craze with a competing class of drugs

Biohaven and other companies are aiming to develop meds with a different mechanism of action that trim the waistline while building lean tissue.

By Kelly Bilodeau • Nov. 20, 2023

​​A startling drop in U.S. life expectancy — and how pharma could help turn the tide

The recently observed dip was particularly acute for men, who now live an average of 5.8 fewer years than women.

By Meagan Parrish • Nov. 17, 2023

AstraZeneca showed the pandemic isn’t over for immunocompromised patients. What’s next?

Dr. Paul Moss, a hematology expert in the U.K., conducted a study with AstraZeneca showing the alarming extent to which immunocompromised patients are burdened with COVID-19.

By Michael Gibney • Nov. 16, 2023

The power of genomics-based healthcare remains largely untapped

23andMe co-founder and CEO Anne Wojcicki discusses ways the industry could integrate genomics into healthcare.

By Alexandra Pecci • Nov. 15, 2023

6 ways to improve clinical trial diversity — as shown by J&J

Johnson & Johnson Innovative Medicine’s director of diversity, equity and inclusion in clinical trials shares key strategies for making DEI work.

By Alexandra Pecci • Nov. 14, 2023

Humans can’t shake the mosquito threat. Here’s what pharma has in the pipeline.

The arsenal against the world’s deadliest creature is growing and a universal vaccine is in the works.

By Kelly Bilodeau • Nov. 13, 2023

Optimizing KOL engagement and technology utilization in 2024

What if your advisory solution was a skillful blend of innovative tech, medical communications specialists, high-touch client service, and a flexible contract?

Nov. 13, 2023

5 of the best paid biopharma CEOs

As revenue growth remained high last year, so did biopharma CEO pay in the U.S.

By Alexandra Pecci • Nov. 10, 2023

How pharma leaders talk about ethics in a highly criticized industry

The maze of ethical issues in biopharma can confound even the wiliest executive. How do some leaders get by?

By Michael Gibney • Nov. 9, 2023

An at-home flu vaccine? If approved, it could open the door to more DIY options

A new way to administer vaccines at home could help AstraZeneca reach a wider market for FluMist, the nasal influenza vaccine.

By Kelly Bilodeau • Nov. 8, 2023

The obesity drug effect: What medical device executives are saying

Investor concerns that interest in GLP-1s will slow demand for medical devices and procedures have shaved roughly $370 billion in value from stocks across the medtech sector, according to research by Mizuho.

By Susan Kelly • Nov. 6, 2023

The thorniest questions facing pharma, according to a leading bioethicist

Bioethics guru Arthur Caplan of NYU gives his outspoken and frank opinion on the industry’s minefield of ethical challenges.

By Michael Gibney • Nov. 6, 2023

PharmaVoice 100s: Entrepreneurs

From biotech startups to a services agency, these entrepreneurs are hedging their bets to offer innovative approaches in patient care.

By Meagan Parrish • Nov. 3, 2023

How Big Pharma keeps the oncology engines hot with a host of strategies

From Merck and J&J to AbbVie and Eisai, the oncology field has stayed consistently devoted to churning out important therapies.

By Michael Gibney • Nov. 2, 2023

Tools like ChatGPT can personalize clinical trials tech — if companies avoid the pitfalls

From hallucinations to data privacy, pharma looks to iron out the kinks of generative AI.

By Kelly Bilodeau • Nov. 1, 2023

Wisp’s ‘bold and unapologetic approach’ to women’s sexual and reproductive health

In the role of interim CEO of Wisp, Monica Cepak aims to break down barriers and expand access via telehealth.

By Alexandra Pecci • Oct. 31, 2023

Roivant’s $7B Roche deal was a ‘moment of opportunity,’ CEO says

Roivant Sciences CEO Matt Gline and Telavant CEO Frank Torti know Roivant’s position as buyers and sellers in the pharma industry, and they’re embracing those opportunities.

By Michael Gibney • Oct. 31, 2023